Obalon Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

SAN DIEGO, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, Obalon's President and Chief Financial Officer, and Bob MacDonald, the Company's Chief Retail Officer will present a corporate overview at the Canaccord Genuity 39th Annual Growth Conference taking place August 7-8, 2019 in Boston.                                                                                  

Presentation Details:

Date and Time: Thursday, August 8, 2019, 9:00am ET

Location: InterContinental Hotel, Boston, MA

A webcast of the live presentation will be accessible at http://wsw.com/webcast/canaccord35/obln/ and will be archived for 90 days following the event. 

About Obalon Therapeutics, Inc.

Obalon Therapeutics, Inc. (NASDAQ: OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. For more information, please visit http://www.obalon.com/.

For Obalon Therapeutics, Inc.

Investor Contact:

William Plovanic

President and Chief Financial Officer

Obalon Therapeutics, Inc.

Office: +1 760 607 5103

wplovanic@obalon.com

Obalon_Logo_Teal_2c.jpg

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!